| Followers | 933 |
| Posts | 159635 |
| Boards Moderated | 2 |
| Alias Born | 08/13/2010 |
Monday, December 19, 2022 9:21:05 PM
$MDGL has $49.81M DEBT, Book value is only $.62
Bearish
Nothing I say, post, or do should ever be considered financial advice. I may be holding a long, short or no position. I am NOT or NEVER have I been compensated to post on here or anywhere and all my posts are for entertainment purposes only.
Recent MDGL News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 10:01:53 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/22/2026 08:34:43 PM
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/21/2026 08:05:00 PM
- Madrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk • GlobeNewswire Inc. • 05/20/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/18/2026 09:36:12 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/18/2026 09:34:52 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/15/2026 04:37:40 PM
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/07/2026 08:05:00 PM
- Madrigal’s (MDGL) MASH Strategy Reiinforced By Rezdiffra Sales Growth and Pipeline Expansion • IH Market News • 05/06/2026 02:46:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/06/2026 01:04:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:06:34 AM
- Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline • GlobeNewswire Inc. • 05/05/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/28/2026 08:22:15 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/28/2026 08:17:02 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/28/2026 08:13:24 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/28/2026 08:05:35 PM
- Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026 • GlobeNewswire Inc. • 04/22/2026 12:00:00 PM
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/21/2026 08:05:00 PM
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/07/2026 08:05:00 PM
- The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step • PR Newswire (Canada) • 04/01/2026 12:49:00 AM
- The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step • PR Newswire (US) • 04/01/2026 12:49:00 AM
- Advanced Cell-based Therapy Booming the Success for Healthcare Sector • PR Newswire (Canada) • 03/24/2026 02:00:00 PM
- Advanced Cell-based Therapy Booming the Success for Healthcare Sector • PR Newswire (US) • 03/24/2026 02:00:00 PM
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/19/2026 08:05:00 PM
